Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Amicus Therapeutics Inc Market Cap
The Amicus Therapeutics Inc (FOLD) share price is expected to increase by 51.18% over the next year. This is based on calculating the average 12-month share price estimate provided by 2 stock analysts who have covered FOLD. Price targets range from $20.00 at the low end to $21.00 at the high end. The current analyst consensus for FOLD is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Amicus Therapeutics Inc has a total of 2 Wall St Analyst ratings. There are 2 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Amicus Therapeutics Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| ritu baral TD Cowen | Buy | None | maintained | Jan 9, 2024 |
| gil blum Needham | Hold | None | maintained | Jan 9, 2024 |
| joseph schwartz Leerink Partners | Buy | None | reiterated | Jan 7, 2024 |
| jeffrey hung Morgan Stanley | Buy | $20.0 | upgraded | Dec 19, 2023 |
| anupam rama J.P. Morgan | Buy | $21.0 | maintained | Nov 28, 2023 |
| dae gon ha Stifel Nicolaus | Buy | $20.0 | maintained | Nov 10, 2023 |
| andrew galler Morgan Stanley | Hold | $15.0 | maintained | Nov 8, 2023 |
| tazeen ahmad Bank of America Securities | Buy | $19.0 | reiterated | Nov 8, 2023 |
| eliana merle UBS | Buy | $20.0 | maintained | Sep 29, 2023 |
| kristen kluska Cantor Fitzgerald | Buy | $18.0 | maintained | Jul 18, 2023 |
| zhiqiang shu Berenberg Bank | Hold | $12.0 | maintained | May 10, 2023 |
| yun zhong BTIG | Buy | $16.0 | reiterated | Mar 2, 2023 |
| salveen richter Goldman Sachs | Hold | $11.0 | maintained | Mar 2, 2023 |
| geulah livshits Chardan Capital | Hold | None | rated | Jul 30, 2021 |
| michael ulz Morgan Stanley | Hold | None | rated | Mar 12, 2021 |
| mohit bansal Wells Fargo | Hold | $16.0 | maintained | Feb 12, 2021 |
| debjit chattopadhyay Guggenheim | Buy | $20.0 | reiterated | Aug 11, 2020 |
| elemer piros Roth Capital | Buy | $19.0 | maintained | Jun 5, 2019 |
| whitney ijem Canaccord Genuity | Buy | $18.0 | initiatedcoverage | Dec 17, 2018 |
| savita subramanian Bank of America Securities | Buy | $10.0 | reiterated | May 20, 2016 |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
When did it IPO
2007
Staff Count
484
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Bradley L. Campbell M.B.A.
Market Cap
$4.02B
In 2023, FOLD generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that FOLD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
$48.92
IPGP-USD
$86.28
ACAD-USD
$24.85
LNTH-USD
$57.46
MRTX-USD
$58.7
PGNY-USD
$40.78
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
